Antimitochindrial and antinuclear antibodies in primary biliary cholangitis

Dana Saipiyeva, Manarbek B. Askarov, Turlybek Tuganbekov, Kulsara Rustemova, Vladimir Grigorevsky, Dossatayeva G.S., Nina Tostanovskaya

Journal of Clinical Medicine of Kazakhstan, 2019

Full text Open access: Gold Metadata (CSL-JSON)

DOI 10.23950/1812-2892-jcmk-00681

Data confidence 70 medium

How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

In this work we reviewed the key antimitochondrial and antinuclear antibodies in primary biliary cholangitis – an autoimmune cholestatic disorder with destruction of intralobular biliary ductules. Since the discovery of antibodies to PDC-E2 component of cholangiocyte mitochondrial membrane, more than 60 antimitochindrial and antinuclear antibodies against various cellular components of cholangiocytes have been described to date, which have primary diagnostic and clinical value in identifying the disease progression and prognosis.